Silence Therapeutics gets patent for siRNA delivery; Drug delivery has impact on patient compliance;

> Silence Therapeutics awarded a patent for its siRNA delivery system, called AtuPLEX. More here

> Nano lipid carriers "are a smarter generation of drug delivery carriers for lovastatin." Abstract

> Report says drug-delivery innovations matter when it comes to patient compliance. Release

> Gold nanoshells are getting ready to leave the lab and, possibly, "change the way we think about drug delivery." Blog post

Drug delivery patent of the week: Cancer cell diagnosis by targeting delivery of nanodevices. Patent

And Finally... A "talking" epinephrine delivery device, e-cue by Intelliject, has received tentative FDA approval, but will it give a verbal "cease-and-desist" due to litigation over the tech? The story

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.